Soleno Therapeutics (SLNO) Assets Average (2014 - 2026)
Soleno Therapeutics (SLNO) posted quarterly Assets Average of $586.1 million for Q1 2026, up 80.6% year-over-year from $324.5 million in Q1 2025, and up 0.73% quarter-over-quarter from $581.9 million in Q4 2025.
Soleno Therapeutics (SLNO) Assets Average (2014 - 2026) Analysis & Trends
Soleno Therapeutics (SLNO) has reported Assets Average for 13 consecutive years, with $586.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average rose 80.6% year-over-year to $586.1 million; the TTM figure through Mar 2026 stood at $586.1 million (up 80.6% YoY), while the FY2025 annual figure was $447.4 million, up 74.88% from the prior year.
- Assets Average advanced to $586.1 million in Q1 2026 per SLNO's latest filing, from $581.9 million in the prior quarter.
- Across five years, Assets Average topped out at $586.1 million in Q1 2026 and bottomed at $23.0 million in Q1 2023.
- Historically, Assets Average has averaged $215.8 million across 5 years, with a median of $174.8 million in 2024.
- Annual changes were most pronounced in 2023 — Assets Average slumped 41.06% — and 2024, when it surged 836.96%.
- Soleno Therapeutics' Assets Average stood at $29.2 million in 2022, then jumped by 317.67% to $122.1 million in 2023, then soared by 156.99% to $313.8 million in 2024, then soared by 85.4% to $581.9 million in 2025, then climbed by 0.73% to $586.1 million in 2026.
- Business Quant data shows SLNO's Assets Average at $586.1 million in Q1 2026, $581.9 million in Q4 2025, and $466.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Soleno Therapeutics | 2.74 Bn | 2.49 Bn | 93.41 Mn | 586.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 586.11 Mn |
| Dec 31, 2025 | 581.86 Mn |
| Sep 30, 2025 | 466.10 Mn |
| Jun 30, 2025 | 325.20 Mn |
| Mar 31, 2025 | 324.53 Mn |
| Dec 31, 2024 | 313.84 Mn |
| Sep 30, 2024 | 300.42 Mn |
| Jun 30, 2024 | 236.48 Mn |
| Mar 31, 2024 | 174.76 Mn |
| Dec 31, 2023 | 122.12 Mn |
| Sep 30, 2023 | 47.25 Mn |
| Jun 30, 2023 | 25.24 Mn |
| Mar 31, 2023 | 23.02 Mn |
| Dec 31, 2022 | 29.24 Mn |
| Sep 30, 2022 | 34.42 Mn |
| Jun 30, 2022 | 39.70 Mn |
| Mar 31, 2022 | 39.05 Mn |
| Dec 31, 2021 | 39.06 Mn |
| Sep 30, 2021 | 45.67 Mn |
| Jun 30, 2021 | 52.74 Mn |